• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    What Labcorp Holdings (LH)'s New PTEN Test and Guidance Hike Means For Shareholders

    Simply Wall St·08/09/2026 13:29:08
    Listen to the news
    • In early August 2026, Labcorp announced nationwide availability of Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay for identifying PTEN protein loss in prostate cancer, alongside reporting higher quarterly sales and earnings and modestly raising its full-year 2026 revenue growth guidance.
    • This combination of expanding precision oncology capabilities and improved financial performance highlights how Labcorp is deepening its role in personalized cancer care while reinforcing its core diagnostics business.
    • We’ll now examine how Labcorp’s new FDA-approved PTEN companion diagnostic may influence its investment narrative and precision oncology ambitions.

    Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

    Labcorp Holdings Investment Narrative Recap

    To own Labcorp, you need to believe its broad diagnostics scale can steadily compound value while newer precision oncology services deepen its moat. The new FDA-approved PTEN companion test and solid recent results support that precision oncology catalyst, but do not materially change nearer term risks around reimbursement pressure, including potential PAMA-related cuts, or competitive pricing in core lab contracts.

    The PTEN assay launch fits neatly alongside Labcorp’s Marker Genetic Health Panel introduced through Labcorp OnDemand, which extends its genetics footprint from oncology into broader hereditary risk assessment. Together, these offerings align with the company’s push toward higher value testing and use of technology, a key driver in its catalyst set, even as high debt levels and possible policy changes remain important watchpoints.

    Yet despite these growth-oriented moves, investors should be aware that reimbursement and policy risks like PAMA could still...

    Read the full narrative on Labcorp Holdings (it's free!)

    Labcorp Holdings’ narrative projects $16.6 billion revenue and $1.4 billion earnings by 2029. This requires 5.0% yearly revenue growth and a roughly $0.4 billion earnings increase from $1.0 billion today.

    Uncover how Labcorp Holdings' forecasts yield a $326.81 fair value, in line with its current price.

    Exploring Other Perspectives

    LH 1-Year Stock Price Chart
    LH 1-Year Stock Price Chart

    Three Simply Wall St Community valuations for Labcorp cluster between US$260 and about US$326.8 per share, underscoring how differently individuals weigh precision oncology launches against ongoing reimbursement and pricing risks in diagnostics, so it is worth comparing several of these viewpoints side by side.

    Explore 3 other fair value estimates on Labcorp Holdings - why the stock might be worth 19% less than the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Ready For A Different Approach?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.